Parallel Advisors LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Parallel Advisors LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,912 shares of the company’s stock after purchasing an additional 2,911 shares during the quarter. Parallel Advisors LLC’s holdings in Johnson & Johnson were worth $4,129,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Virtus ETF Advisers LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth $25,000. Krane Funds Advisors LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $26,000. Financial Advantage Inc. acquired a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $28,000. Crewe Advisors LLC boosted its position in shares of Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the last quarter. Finally, Permanens Capital L.P. boosted its position in shares of Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after acquiring an additional 100 shares during the last quarter. 72.22% of the stock is owned by hedge funds and other institutional investors.

NYSE JNJ traded down $0.68 during trading hours on Tuesday, reaching $131.30. The company had a trading volume of 258,536 shares, compared to its average volume of 8,718,446. The stock has a 50-day moving average of $130.89 and a 200 day moving average of $134.00. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $350.04 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 2.25 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter in the prior year, the company posted $2.05 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 8.65 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $0.95 dividend. The ex-dividend date is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a yield of 2.89%. Johnson & Johnson’s payout ratio is currently 46.45%.

JNJ has been the topic of several recent research reports. Wells Fargo & Co lowered their price target on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 16th. Credit Suisse Group boosted their price target on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a research report on Friday, October 11th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Finally, Bank of America reissued a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $151.64.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Stop Order

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.